Eris Lifesciences Ltd

As of June 30, 2026, Eris Lifesciences Ltd carries a market capitalization of 198.65B, placing it among publicly traded companies globally. Its enterprise value stands at 198.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eris Lifesciences Ltd's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Eris Lifesciences Ltd has 138.58M shares outstanding.

As of June 30, 2026, Eris Lifesciences Ltd trades at a trailing price-to-earnings ratio of 30.48.

As of June 30, 2026, Eris Lifesciences Ltd trades at an EV/EBITDA multiple of 17.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 198.65B versus a market cap of 198.65B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 9.68M in revenue per employee across its workforce of 3,317.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Eris Lifesciences Ltd recorded an income tax benefit of -88.00M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 6.57B, leaving 6.44B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Eris Lifesciences Ltd's stock has declined approximately 29.28% over the past 52 weeks. The 50-day moving average sits at 1,267.75, while the 200-day moving average is 1,362.46.

Over the twelve months ended June 30, 2026, Eris Lifesciences Ltd generated 32.12B in revenue and converted that into 6.44B in net income, yielding earnings per share of 48.56. EBITDA reached 11.22B, while operating income came in at 8.59B.

Over the twelve months ended June 30, 2026, Eris Lifesciences Ltd posted a gross margin of 73.53, reflecting its pricing power and cost economics. The operating margin of 26.73 and net profit margin of 20.04 provide insight into operational efficiency.